Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect ...

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company ...

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and ...

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases ...

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

“Larvae without vestibular sensory experience, but whose neuromuscular junction was mature, had a strong vestibulo-ocular reflex. Development of the neuromuscular junction, and not sensory experience, ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.